REGENXBIO Inc. (RGNX)
| Market Cap | 491.80M +0.9% |
| Revenue (ttm) | 174.48M +12.0% |
| Net Income | -196.43M |
| EPS | -3.77 |
| Shares Out | 66.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,096,030 |
| Open | 7.41 |
| Previous Close | 7.47 |
| Day's Range | 7.33 - 7.64 |
| 52-Week Range | 5.46 - 16.19 |
| Beta | 1.13 |
| Analysts | Buy |
| Price Target | 23.73 (+218.52%) |
| Est. Earnings | Nov 5, 2026 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-12... [Read more]
Financial Performance
In 2025, REGENXBIO's revenue was $170.44 million, an increase of 104.54% compared to the previous year's $83.33 million. Losses were -$193.88 million, -14.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for RGNX stock is "Buy." The 12-month stock price target is $23.73, which is an increase of 218.52% from the latest price.
News
Regenxbio presents positive 3-year durability data for Surabgene Lomparvove
REGENXBIO (RGNX) “announced positive long-term follow-up data from the Phase II ALTITUDE(R) study of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy using suprac...
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no a...
REGENXBIO Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted late-stage progress in gene therapies for DMD and retinal diseases, with RGX-202 showing strong efficacy, safety, and regulatory momentum toward a 2027 launch. The retina franchise is advancing with pivotal data expected and robust commercial planning, while the Hunter program's clinical hold is under active review.
REGENXBIO Transcript: 2026 Global Healthcare Conference
The conference highlighted late-stage gene therapy programs with strong clinical data in DMD and retina, robust regulatory engagement, and a solid financial runway into 2027. Key programs are advancing toward pivotal data and regulatory filings, with global strategies and commercial readiness underway.
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference Fireside ...
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
SAN DIEGO--(BUSINESS WIRE)---- $RGNX #BiotechInvesting--Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against cer...
Regenxbio price target lowered to $21 from $23 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Regenxbio (RGNX) to $21 from $23 and keeps a Buy rating on the shares after the FDA had placed…
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.
Regenxbio price target lowered to $29 from $32 at Baird
Baird analyst Brian Skorney lowered the firm’s price target on Regenxbio (RGNX) to $29 from $32 and keeps an Outperform rating on the shares. The firm updated its model following…
Regenxbio price target lowered to $32 from $45 at Clear Street
Clear Street analyst Bill Maughan lowered the firm’s price target on Regenxbio (RGNX) to $32 from $45 and keeps a Buy rating on the shares. The firm cites the clinical…
RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating REGENXBIO Inc. (NASDAQ: RGNX) on behalf of investors who suffered losses and whether those losses may be recoverable ...
BofA says Regenxbio’s MPS setback ‘disappointing,’ larger catalysts intact
BofA says that the clinical hold on Regenxbio’s (RGNX) RGX-121 — after asymptomatic spine MRI findings in five MPS II participants — is “disappointing” and reverses July’s progress. While Regenxbio…
Morning Movers: Regenxbio sinks following clinical hold on RGX-121
Stock futures are pointing to a weaker open as the market comes off a losing week for all three major indexes, with technology stocks particularly pressured by the recent rise…
Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial
Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company's investigational therapy for Hunter syndome.
Regenxbio to resume trading at 7:25 am ET
Regenxbio (RGNX) is scheduled to resume quoting at 7:20 am ET and to resume trading at 7:25 am ET, according to Nasdaq. Shares were halted, pending news, ahead of the…
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
Regenxbio said on Monday the U.S. Food and Drug Administration has placed its experimental gene therapy for Hunter syndrome on clinical hold after spinal scans found abnormalities in five study p...
Regenxbio reports FDA placed clinical hold on RGX-121
Regenxbio (RGNX) provided an update on its investigational gene therapy, RGX-121, for the treatment of Mucopolysaccharidosis type II, also known as Hunter Syndrome. The U.S. Food and Drug Administrati...
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucop...
Regenxbio price target lowered to $23 from $26 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $23 from $26 and keeps a Buy rating on the shares post the Q2 report. The firm cites the…
Regenxbio price target raised to $18 from $16 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Regenxbio (RGNX) to $18 from $16 and keeps an Overweight rating on the shares.
Regenxbio downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Eliana Merle downgraded Regenxbio (RGNX) to Equal Weight from Overweight with an unchanged price target of $12. The firm sees potential upside for the company’s wholly-owned RGX-202 f...
REGENXBIO Earnings Call Transcript: Q2 2026
Key milestones achieved in late-stage gene therapy programs, including full enrollment in pivotal studies and FDA alignment for accelerated approval. Financial position strengthened with over $310 million pro forma cash, supporting a runway into Q4 2027 and multiple upcoming regulatory and commercial milestones.
REGENXBIO Earnings release: Q2 2026
REGENXBIO released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
REGENXBIO Quarterly report: Q2 2026
REGENXBIO has published its Q2 2026 quarterly earnings report on August 6, 2026.
Regenxbio reports Q2 EPS 43c vs. ($1.38) last year
Reports Q2 revenue $108M, consensus $96.46M. “Our second quarter was defined by strong clinical execution across our pipeline: the Phase III AFFINITY DUCHENNE trial met its primary endpoint, we dosed…